Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of “Buy” from Brokerages

Humacyte, Inc. (NASDAQ:HUMA) has earned an average rating of “Buy” from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $10.00.

HUMA has been the topic of several analyst reports. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 target price on shares of Humacyte in a research report on Friday, September 20th. Benchmark reissued a “buy” rating and issued a $15.00 target price on shares of Humacyte in a research report on Thursday, October 10th. BTIG Research reissued a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. Finally, TD Cowen reissued a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th.

Humacyte Stock Down 1.8 %

Shares of NASDAQ HUMA opened at $5.32 on Wednesday. Humacyte has a 1 year low of $1.96 and a 1 year high of $9.97. The firm’s 50 day moving average price is $5.66 and its 200 day moving average price is $6.05. The firm has a market cap of $633.53 million, a P/E ratio of -5.32 and a beta of 1.45. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 5.41.

Humacyte (NASDAQ:HUMA) last announced its earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). As a group, sell-side analysts anticipate that Humacyte will post -1.09 earnings per share for the current year.

Insider Activity

In other Humacyte news, Director Kathleen Sebelius sold 5,182 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total transaction of $27,982.80. Following the completion of the transaction, the director now directly owns 40,276 shares of the company’s stock, valued at $217,490.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Humacyte news, Director Brady W. Dougan sold 252,676 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the completion of the transaction, the director now directly owns 4,306,464 shares of the company’s stock, valued at $28,896,373.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Kathleen Sebelius sold 5,182 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total transaction of $27,982.80. Following the transaction, the director now directly owns 40,276 shares of the company’s stock, valued at $217,490.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 1,084,153 shares of company stock valued at $6,869,996. Company insiders own 23.10% of the company’s stock.

Institutional Trading of Humacyte

Institutional investors have recently made changes to their positions in the stock. nVerses Capital LLC acquired a new stake in shares of Humacyte in the 2nd quarter worth approximately $28,000. Principal Financial Group Inc. acquired a new stake in shares of Humacyte in the 2nd quarter worth approximately $83,000. Profund Advisors LLC acquired a new stake in shares of Humacyte in the 2nd quarter worth approximately $97,000. Hartline Investment Corp acquired a new stake in shares of Humacyte in the 1st quarter worth approximately $70,000. Finally, XTX Topco Ltd acquired a new stake in shares of Humacyte in the 2nd quarter worth approximately $110,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.